TAS-102, also known as a combination of trifluridine and tipiracil, is an oral medication primarily used in the treatment of metastatic colorectal cancer. It functions as an antineoplastic agent, where trifluridine acts as a nucleoside analog that interferes with DNA synthesis, while tipiracil inhibits the enzyme thymidine phosphorylase, thereby enhancing the bioavailability of trifluridine. This combination allows for effective targeting of cancer cells while minimizing systemic toxicity. TAS-102 is typically administered in a specific dosing regimen, and its efficacy has been demonstrated in clinical trials, showing improved survival rates in patients with refractory colorectal cancer. The substance is characterized by its unique mechanism of action, which combines both cytotoxic and pharmacokinetic properties, making it a valuable option in oncology. As with any chemotherapeutic agent, potential side effects may include myelosuppression, gastrointestinal disturbances, and fatigue, necessitating careful monitoring during treatment.

TAS 102

2300074-31-9: TAS-102, also known as a combination of trifluridine and tipiracil, is an oral medication primarily used in the treatment of metastatic colorectal cancer. It functions as an antineoplastic agent, where trifluridine acts as a nucleoside analog that interferes with DNA synthesis, while tipiracil inhibits the enzyme thymidine phosphorylase, thereby enhancing the bioavailability of trifluridine. This combination allows for effective targeting of cancer cells while minimizing systemic toxicity. TAS-102 is typically administered in a specific dosing regimen, and its efficacy has been demonstrated in clinical trials, showing improved survival rates in patients with refractory colorectal cancer. The substance is characterized by its unique mechanism of action, which combines both cytotoxic and pharmacokinetic properties, making it a valuable option in oncology. As with any chemotherapeutic agent, potential side effects may include myelosuppression, gastrointestinal disturbances, and fatigue, necessitating careful monitoring during treatment.

<p>KRN7000 analog 8 (compound 8) is a variant of KRN7000 that demonstrates a strong stimulatory effect on IL-2 production. Compared to KRN7000, it induces lower levels of IFN-γ but results in higher IL-4 production.</p>

CAS 2300074-31-9

TAS 102

KRN7000 analog 8

Ref: TM-T203474